0
Abstract: Poster Presentations |

WEEKLY PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY WITH CONCOMITANT RADIOTHERAPY IN LOCALLY ADVANCED INOPERABLE NON-SMALL CELL LUNG CANCER (NSCLC) FREE TO VIEW

Irena Spasova, MD, PhD*; Roman Pajdlhauser, MD; Zdenek Skacel, MD; Miloslav Marel; Jaromir Musil
Author and Funding Information

Pulmonary Department, University Hospital Motol in Prague, Prague, Czech Republic



Chest. 2006;130(4_MeetingAbstracts):233S. doi:10.1378/chest.130.4_MeetingAbstracts.233S-a
Text Size: A A A
Published online

Abstract

PURPOSE: To assess efficacy and toxicity of weekly low-dose paclitaxel given combined with four weekly carboplatin concomitantly with radiotherapy in locally advanced NSCLC patients (pts). To evaluate response rate, time to progression and median survival time.

METHODS: Prospective phase II study. 18 pts (17 male/1 female) involved, median age 63 years (46-71) with newly diagnosed NSCLC, clinical stage IIIA/IIIB (6/12), PS 0-1 (11/7). Chemotherapy naive pts received four cycles of paclitaxel 100 mg/m2 (reduced to 50 mg/m2 during radiation) on day 1, 8, and 15 and carboplatin AUC 6 in day 1, in 28 days cycles. Concomitant normofractionated external beam irradiation to primary tumor and regional lymph nodes (65,0-71,0 Gy/fraction 1,8-2,0 Gy/5 fraction/week) was administred in patients free of progression since the third cycle.

RESULTS: The median number of paclitaxel infusions administered per pts was 12 (3-12) and 4 infusions of carboplatin (1-4). 15 pts received radiotherapy. The most frequent hematological toxicities were neutropenia and leukopenia (grade 3/4 both in 17% of pts) and anemia (11% of pts). Grade 3/4 esophagitis occured in 3 (17%) and pneumonitis in 2 (11%) of pts. No toxic death occurred. 13 pts had partial response (72%), 3 stable (17%) and 2 progressive disease (11%). Median progression free survival was 35 weeks (6-57), median survival time was 60 weeks, 1-year survival 55% with a median follow-up 18 months.

CONCLUSION: Weekly low-dose paclitaxel combined with four weekly carboplatin chemotherapy administered concomitantly with radiotherapy is an effective treatment in locally advanced NSCLC. The toxicity of this regimen is very low.

CLINICAL IMPLICATIONS: This combined modality treatment is a reasonable option for pts with locally advanced inoperable NSCLC in PS 0-1.

DISCLOSURE: Irena Spasova, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543